Cellular Therapy

BIOLOGICAL6 trials

Conditions

HLA-A*0201 Positive Cells PresentHematologic DiseaseHematopoietic and Lymphoid Cell NeoplasmHemophiliaLocally Advanced Malignant NeoplasmNY-ESO-1 PositiveNY-ESO-1 Positive Tumor Cells PresentPlatinum-Resistant Fallopian Tube Carcinoma

Early Phase 1

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

RecruitingNCT04744116

M.D. Anderson Cancer CenterHematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease

Start: 2021-02-17End: 2026-03-15Target: 24Updated: 2025-11-07

Phase 1

Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia

NCT02108132

Cairo UniversityHemophilia

Start: 2014-08-31End: 2016-02-29Target: 20Updated: 2014-04-09

Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia

NCT02108132

Cairo UniversityHemophilia

Start: 2014-08-31End: 2016-02-29Target: 20Updated: 2014-04-09

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

TerminatedNCT03240861

Jonsson Comprehensive Cancer CenterHLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive +2

Start: 2017-07-26End: 2023-10-19Updated: 2023-11-01

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

WithdrawnNCT03506802

Jonsson Comprehensive Cancer CenterHLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma +1

Start: 2018-07-10End: 2019-06-25Updated: 2020-07-24

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT03691376

Roswell Park Cancer InstitutePlatinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +9

Start: 2019-03-08End: 2024-06-24Updated: 2024-09-19

Unknown Phase

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Active, not recruitingNCT06849921

Ruijin HospitalHematologic Disease, Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

Start: 2024-11-07End: 2030-12-30Target: 200Updated: 2025-02-27

Related Papers

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.

2025-07-01

Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma

Cancer Research2023-04-04

In Search of an Immunotherapy Innovation for Ovarian Cancer

Oncology Times2019-07-11